A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lubiprostone for the Treatment of Chronic Idiopathic Constipation
Phase of Trial: Phase III
Latest Information Update: 24 Apr 2017
At a glance
- Drugs Lubiprostone (Primary)
- Indications Constipation
- Focus Registrational; Therapeutic Use
- Sponsors Takeda
- 19 Apr 2017 Status changed from active, no longer recruiting to completed.
- 12 Jan 2017 Planned primary completion date changed from 1 Apr 2017 to 1 May 2017.
- 12 Jan 2017 Status changed from recruiting to active, no longer recruiting.